AR065740A1 - Composicion topica de poliaphones con vitamina d y corticoide. - Google Patents

Composicion topica de poliaphones con vitamina d y corticoide.

Info

Publication number
AR065740A1
AR065740A1 ARP080101054A ARP080101054A AR065740A1 AR 065740 A1 AR065740 A1 AR 065740A1 AR P080101054 A ARP080101054 A AR P080101054A AR P080101054 A ARP080101054 A AR P080101054A AR 065740 A1 AR065740 A1 AR 065740A1
Authority
AR
Argentina
Prior art keywords
vitamin
composition
ketoneone
poliaphones
topica
Prior art date
Application number
ARP080101054A
Other languages
English (en)
Inventor
David Fraser Steele
Michelle Georgiou
Derek Alfred Wheeler
Steen Sindet-Pedersen
Original Assignee
Drug Delivery Solutions Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0723728A external-priority patent/GB0723728D0/en
Application filed by Drug Delivery Solutions Ltd filed Critical Drug Delivery Solutions Ltd
Publication of AR065740A1 publication Critical patent/AR065740A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una composicion adecuada para la aplicacion topica, que comprende una fase continua y al menos una fase discontinua, dicha composicion comprende al menos una dispersion de poliaphrones, al menos una vitamina D o análogo de vitamina D y al menos uncorticoesteroide. Método para producirla. Reivindicacion 2: Una composicion de acuerdo con la reivindicacion 1, caracterizada porque el corticoesteroide es betametasona, clobetasol, clobetasona, desoximetasona, diflucortolona, difluorasona,fluocinoida, flumetasona, fluocinolona, fluticasona, fluprednideno, halcinonida, hidrocortisona, mometasona, triamcinolona y sus ésteres, o una mezcla de ellos. Reivindicacion 4: Una composicion de acuerdo con cualquiera de las reivindicacionesanteriores, caracterizada porque la vitamina D o el análogo de vitamina D es vitamina D, calcipotriol, seocalcitol, calcitriol, tacalcitol, maxacalcitol, paricalcitol, falecalcitriol, 1alfa,24S-dihidroxi-vitamina D2, 1(S),3( R)-dihidroxi-20( R)-[((3-(2-hidroxi-2-propil)-fenil)-metoxi)-metil]-9,10-secopregna-5-(Z),/Ç,10(19)-trieno, o una mezcla de ellos.
ARP080101054A 2007-03-15 2008-03-14 Composicion topica de poliaphones con vitamina d y corticoide. AR065740A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07251094A EP1970049A1 (en) 2007-03-15 2007-03-15 Polyaphron topical composition with vitamin D and corticosteroid
US11/905,163 US20080227759A1 (en) 2007-03-15 2007-09-27 Topical composition
GB0723728A GB0723728D0 (en) 2007-03-15 2007-12-04 Topical composition

Publications (1)

Publication Number Publication Date
AR065740A1 true AR065740A1 (es) 2009-06-24

Family

ID=38294208

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080101054A AR065740A1 (es) 2007-03-15 2008-03-14 Composicion topica de poliaphones con vitamina d y corticoide.

Country Status (14)

Country Link
US (1) US20080227759A1 (es)
EP (2) EP1970049A1 (es)
JP (1) JP5414542B2 (es)
CN (2) CN101674808A (es)
AR (1) AR065740A1 (es)
AT (1) ATE516797T1 (es)
AU (1) AU2008224704B2 (es)
CA (1) CA2680405C (es)
DK (1) DK2139452T3 (es)
ES (1) ES2368535T3 (es)
RU (1) RU2466716C2 (es)
TW (1) TWI434705B (es)
WO (1) WO2008110815A1 (es)
ZA (1) ZA200906382B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10265265B2 (en) 2007-03-15 2019-04-23 Drug Delivery Solutions Limited Topical composition
EP2008651A1 (en) 2007-06-26 2008-12-31 Drug Delivery Solutions Limited A bioerodible patch
US20120238535A1 (en) * 2009-02-23 2012-09-20 Smith Jan G Topical formulation of low level clobetasol propionate for treating disorders of the skin and mucous membranes
MX2012007227A (es) * 2009-12-22 2012-07-30 Leo Pharma As Composicion farmaceutica que comprende analogo de vitamina d y mezcla de cosolvente-tensioactivo.
RU2560677C2 (ru) * 2009-12-22 2015-08-20 Лео Фарма А/С Кожная композиция, включающая аналог витамина d и смесь растворителя и поверхностно-активных веществ
CN102939078B (zh) 2010-06-11 2014-12-24 利奥制药有限公司 含有维生素d类似物和皮质类固醇的药用喷雾剂组合物
KR101368587B1 (ko) 2010-12-27 2014-03-05 주식회사 삼양바이오팜 오심 또는 구토 방지용 조성물
PT2686017T (pt) * 2011-03-14 2019-10-24 Drug Delivery Solutions Ltd Uma composição oftálmica.
CN104138352B (zh) * 2013-04-19 2018-02-27 江苏知原药业有限公司 卡泊三醇非水凝胶
TWI756168B (zh) 2015-02-02 2022-03-01 日商參天製藥股份有限公司 多微泡及其眼瞼投予
KR101641372B1 (ko) * 2015-05-08 2016-07-20 (주)동구바이오제약 안정성과 피부투과율이 향상된 약학 조성물
US20180235882A1 (en) 2015-09-02 2018-08-23 Cadila Healthcare Limited Topical compositions comprising corticosteroids
GB201604316D0 (en) 2016-03-14 2016-04-27 Avexxin As Combination therapy
EP3463473A1 (en) * 2016-06-03 2019-04-10 Avexxin AS Combination therapy comprising a polyunsaturated ketone and a corticosteroid
US20190209585A1 (en) * 2016-06-03 2019-07-11 Avexxin As Combination therapy comprising a polyunsaturated ketone and a secosteroid
US11351127B2 (en) 2016-09-21 2022-06-07 Avexxin As Pharmaceutical composition
GB201701583D0 (en) 2017-01-31 2017-03-15 Drug Delivery Solutions Ltd Topical composition
BE1026073B1 (nl) * 2018-03-05 2019-10-07 Purna Pharmaceuticals Nv Verbeterde werkwijze voor het maken van een farmaceutische emulsie
EP3542788A1 (en) 2018-03-19 2019-09-25 MC2 Therapeutics Limited Topical composition comprising calcipotriol and betamethasone dipropionate
CN108653195A (zh) * 2018-08-08 2018-10-16 江苏知原药业有限公司 透皮或透粘膜给药制剂
CN114159567B (zh) * 2020-09-10 2023-03-31 南京海融医药科技股份有限公司 一种治疗皮肤病的混悬凝胶剂
CN113267390B (zh) * 2021-05-11 2023-05-05 北京丹大生物技术有限公司 一种用于滤纸干血片的检测标志物洗脱液及其应用
CN115569199A (zh) * 2022-02-14 2023-01-06 南京海融医药科技股份有限公司 一种药物组合物及其制备方法和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3779907A (en) * 1970-04-13 1973-12-18 Exxon Research Engineering Co Liquid membrane process for the separation of aqueous mixtures
GB1541463A (en) * 1975-10-11 1979-02-28 Lion Dentifrice Co Ltd Process for prparing a multiple emulsion having a dispersing form of water-phase/oil-phase/water-phase
US4486333A (en) * 1981-04-10 1984-12-04 Felix Sebba Preparation of biliquid foam compositions
CA1272953A (en) * 1984-10-08 1990-08-21 Yuji Makino Pharmaceutical composition for external use containing active-type vitamin d.sub.3
US4999198A (en) * 1989-03-23 1991-03-12 The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations Polyaphrons as a drug delivery system
PT3146969T (pt) * 1999-04-23 2018-10-18 Leo Pharma As Composição farmacêutica para aplicação dérmica para uso no tratamento da psoríase compreendendo vitamina d e um corticosteroide
DK1331927T3 (da) * 2000-10-27 2008-05-05 Leo Pharma As Topisk komposition der indeholder mindst et D-vitamin eller en D-vitamin analog og mindst et kosttikosteroid
US7415169B2 (en) * 2001-11-30 2008-08-19 Koninklijke Philips Electronics N.V. Medical viewing system and method for enhancing structures in noisy images
GB0317868D0 (en) * 2003-07-30 2003-09-03 Disperse Ltd Biliquid foams with a high alcohol content and products formulated therefrom
GB0404403D0 (en) * 2004-02-27 2004-03-31 Disperse Ltd Dispersions
FR2871696B1 (fr) * 2004-06-17 2006-11-10 Galderma Sa Composition topique pour le traitement du psoriasis

Also Published As

Publication number Publication date
RU2009138045A (ru) 2011-04-20
CA2680405C (en) 2016-08-16
JP2010521445A (ja) 2010-06-24
ES2368535T3 (es) 2011-11-18
TWI434705B (zh) 2014-04-21
DK2139452T3 (da) 2011-11-14
EP1970049A1 (en) 2008-09-17
TW200902084A (en) 2009-01-16
RU2466716C2 (ru) 2012-11-20
AU2008224704B2 (en) 2013-09-12
CN101674808A (zh) 2010-03-17
ATE516797T1 (de) 2011-08-15
ZA200906382B (en) 2010-11-24
CA2680405A1 (en) 2008-09-18
AU2008224704A1 (en) 2008-09-18
CN104815329A (zh) 2015-08-05
EP2139452A1 (en) 2010-01-06
US20080227759A1 (en) 2008-09-18
JP5414542B2 (ja) 2014-02-12
EP2139452B1 (en) 2011-07-20
WO2008110815A1 (en) 2008-09-18

Similar Documents

Publication Publication Date Title
AR065740A1 (es) Composicion topica de poliaphones con vitamina d y corticoide.
Van Driel et al. Vitamin D endocrine system and osteoblasts
Landel et al. Differential expression of vitamin D-associated enzymes and receptors in brain cell subtypes
Ness et al. The role of vitamin D in cancer prevention
Zhou et al. Vitamin D metabolism and action in human bone marrow stromal cells
Wang et al. Human UGT1A4 and UGT1A3 conjugate 25-hydroxyvitamin D3: metabolite structure, kinetics, inducibility, and interindividual variability
Peng et al. 25-Hydroxyvitamin D 3 is a natural chemopreventive agent against carcinogen induced precancerous lesions in mouse mammary gland organ culture
Brown et al. Drug insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease
Noyola-Martínez et al. Regulation of CYP27B1 and CYP24A1 gene expression by recombinant pro-inflammatory cytokines in cultured human trophoblasts
Slatopolsky et al. New vitamin D analogs
Ethier-Chiasson et al. Influence of maternal lipid profile on placental protein expression of LDLr and SR-BI
Gallagher et al. Falls are associated with decreased renal function and insufficient calcitriol production by the kidney
Hidalgo et al. Glucocorticoid regulation of the vitamin D receptor
JP2008297309A5 (es)
RU2008100037A (ru) Способ регулируемого высвобождения лекарственного средства через кожу
Bonhomme et al. Vitamin A status regulates glucocorticoid availability in Wistar rats: consequences on cognitive functions and hippocampal neurogenesis?
BR112022001402A2 (pt) Método para a fabricação de material de folha de susceptor que compreende um gel formador de aerossol e sistema de dosagem
Takada et al. Therapeutic application of vitamin D receptor ligands: an updated patent review
Bouillon et al. Mechanisms for the selective action of Vitamin D analogs
BRPI0510639A (pt) composto ou um sal ou uma pró-droga farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos de tratar ou prevenir distúrbios, de terapia de reposição hormonal, de abaixar nìveis de colesterol, triglicerìdeos ou ldl, de tratar cognição prejudicada ou prover neuroproteção, de prevenir concepção, de modular ou agonizar especificamente um ou mais receptores de estrogênio e, uso de um composto
Chen et al. 1, 25-Dihydroxy vitamin D3 stimulates system A amino acid transport in primary human trophoblast cells
Paschoalin et al. Cinacalcet de novo in persistent hypercalcemia after kidney transplantation secondary to hyperparathyroidism: long-term follow-up and effect of withdrawal
Cidem et al. Serum sclerostin is decreased following vitamin D treatment in young vitamin D-deficient female adults
ECSP088567A (es) Composiciones farmaceuticas que comprenden derivados de esteroides sintéticos, minerales y el metabolito activo de la vitamina d, 1,25(oh)2d3 (calcitriol) para la prevención y tratamiento de la osteoporosis y el control de los síntomas de la menopaus
BR112014017834A8 (pt) Sistema de distribuição de fármacos

Legal Events

Date Code Title Description
FB Suspension of granting procedure